Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

This study has been terminated.
(The study was terminated early following assessment of the two co-primary endpoints showing the lack of efficacy of the study product.)
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: November 21, 2008
Last updated: September 29, 2016
Last verified: September 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: January 2016
  Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: November 16, 2012